oasis 1 oral semaglutide 50 mg nejm 2023 obesity Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/49ERpN9

29.19

★★★★☆4.8 (126)

For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral semaglutide at a dose of 50 mg

24.22

★★★★★4.9 (98)

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

27.49

★★★★★5.0 (157)

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

21.01

★★★★★4.7 (84)

50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj

26.98

★★★★★4.9 (203)

Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity

28.00

★★★★★5.0 (176)

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

26.54

★★★★★4.8 (132)